ProCE Banner Activity

Phase II FRACTION-RCC Adaptive Design Trial: Nivolumab + Ipilimumab in Advanced RCC Progressing After Checkpoint Inhibitor Therapy

Slideset Download
Conference Coverage
A subset of patients with advanced RCC previously treated with checkpoint inhibitors responded to subsequent treatment with nivolumab + ipilimumab.

Released: June 01, 2020

Expiration: May 31, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono